Neurobo Pharmaceuticals Inc   (NRBO)
Other Ticker:  
Price: $5.5900 $0.29 5.472%
Day's High: $5.67 Week Perf: 4.49 %
Day's Low: $ 5.35 30 Day Perf: 79.17 %
Volume (M): 82 52 Wk High: $ 7.60
Volume (M$): $ 461 52 Wk Avg: $4.27
Open: $5.35 52 Wk Low: $2.89

 Market Capitalization (Millions $) 28
 Shares Outstanding (Millions) 5
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) 19
 Capital Exp. (TTM) (Millions $) 0

Neurobo Pharmaceuticals Inc
Neurobo Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that focuses on the development of novel therapies for the treatment of neurological and neuromuscular diseases. The company is dedicated to addressing unmet medical needs and improving the lives of patients suffering from debilitating conditions. Neurobo Pharmaceuticals is known for its research and development efforts in neurology, where it aims to discover and develop innovative drugs that can potentially provide therapeutic benefits to patients. The company's pipeline includes candidates for conditions such as diabetic neuropathy, Alzheimer's disease, and neurodegenerative disorders. Neurobo Pharmaceuticals is committed to advancing its drug candidates through clinical trials and regulatory processes to ultimately deliver effective treatments to patients in need.

   Company Address: 545 Concord Avenue, Suite 210 Cambridge, 2138 MA
   Company Phone Number: 702-9600   Stock Exchange / Ticker: NASDAQ NRBO
   NRBO is expected to report next financial results on March 29, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Neurobo Pharmaceuticals Inc

Neurobo Pharmaceuticals Inc. Unveils Remarkable Q3 2023 Results Amidst Stiff Industry Competition

As the reporting cycle for the July to September 2023 quarter progresses, the financial performance of various companies is being closely monitored. Among them, Neurobo Pharmaceuticals Inc, a prominent player in the Major Pharmaceutical Preparations industry, recently disclosed an operating shortfall of $-3.893 million for the third quarter of 2023. While specific revenue figures have not been released yet, it is imperative to analyze Neurobo Pharmaceuticals' previous financial records to gain a contextual understanding of current top-line performance.
Operating Shortfalls and Context:
Examining the operating shortfall of $-3.104 million recorded by Neurobo Pharmaceuticals in the third quarter of 2022 offers a basis for comparison. Although the company experienced a deficit during that period, it is not uncommon for businesses to encounter challenging periods on their path towards generating significant revenue streams. Unfortunately, the financial period ending on September 30, 2023, has presented further obstacles, resulting in an extended operating shortfall of $-3.818 million.

Neurobo Pharmaceuticals Inc

Neurobo Pharmaceuticals Inc Reports Decreased Operating Losses, Signaling Positive Financial Trend in Q2 2023

Neurobo Pharmaceuticals Inc is a pharmaceutical company that recently reported its second quarter results for 2023. The company experienced an operating loss of $-3.806 million during this period and did not generate any revenue. This article will provide an extensive overview of Neurobo Pharmaceuticals Inc, its financial performance, and its current standing in the market.
The company's financial report for the second quarter of 2023 showed a decrease in operating loss compared to the same period in 2022. In 2022, Neurobo Pharmaceuticals Inc reported an operating loss of $-3.219 million, indicating an improvement in the company's bottom-line. This positive development is a significant conclusion from the fiscal interval ending June 30, 2023. The shortfall in the second quarter of 2023 was $-0.734 million, significantly lower than the $-3.303 million reported in the second quarter of 2022.

Neurobo Pharmaceuticals Inc

Neurobo Pharmaceuticals Inc's Ambitious Research Efforts Overshadowed by Disappointing Financial Results, Leave Investors Concerned

Neurobo Pharmaceuticals Inc, a pioneering pharmaceutical research company, recently announced its financial results for the 12 months ending in the first quarter of 2023. Unfortunately, the figures were not as positive as the company had hoped for, with a cumulative net loss of $-14 million, resulting in a negative return on equity (ROE) of -96.06%.
looking at the performance within the Major Pharmaceutical Preparations industry, Neurobo Pharmaceuticals Inc was ranked below 181 other companies with a higher return on equity. These figures are certainly concerning for investors who have placed their faith in the company's research capabilities.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com